FDA grants orphan drug designation to Miragen Therapeutics

Miragen Therapeutics, a leading biopharmaceutical company has announced that US Food and Drug Administration have granted orphan drug designation to its novel product, MRG-106 .

Release Date: 12-Apr-2017



Miragen Therapeutics, a leading biopharmaceutical company has announced that US Food and Drug Administration have granted orphan drug designation to its novel product, MRG-106 for the treatment of mycosis fungoides.
The orphan drug designation is granted to investigational drugs intended to treat rare diseases affecting fewer than 200,000 people nationwide. The status has the potential to provide several benefits to developers, including tax credits for clinical trials costs, exemptions from certain FDA application fees and seven years of market exclusivity upon approval.
“Global Orphan Drug Clinical Pipeline Insight” reports by kuick research gives comprehensive insight on various clinical and non-clinical aspects associated with ongoing clinical trials of 808 orphan designated drugs across the globe. The in-depth clinical insight presented in the report helps the reader to analyze and identify the various stakeholders involved in the clinical development and commercialization of orphan designated drugs in the global market. Currently there are more than 300 orphan designated drugs commercially available in the global market and around 800 drugs in clinical development phase.
 
 
For Orphan Drug Clinical Insight Reports Contact:  neeraj@kuickresearch.com          

Need custom market research solution? We can help you with that too.